JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266058

Human MYPN knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

MYPN KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human MYPN knockout HeLa cell line (AB266058)
  • Sanger seq

Unknown

Sanger Sequencing - Human MYPN knockout HeLa cell line (AB266058)

Homozygous : 1 bp insertion in exon2

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266058-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266058-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266058 Human MYPN knockout HeLa cell line", "number":"AB266058-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266058-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266058 Human MYPN knockout HeLa cell line", "number":"AB266058-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB266058-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266058-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266058 Human MYPN knockout HeLa cell line", "number":"AB266058-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266058-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266058 Human MYPN knockout HeLa cell line", "number":"AB266058-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
MYPN
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The MYPN protein also known as myopalladin weighs around 145 kDa. Scientists find MYPN in skeletal and cardiac muscle tissues where it plays a critical role in muscle structure and function. This protein associates with actin filaments and alpha-actinin regulating the organization and stability of the sarcomere the fundamental unit of muscle contraction. By interacting with proteins in the Z-disc MYPN acts as a scaffold which aids in maintaining the architecture necessary for force transmission.
Biological function summary

Myopalladin influences muscle contractility by integrating signals and structural elements in the sarcomere. MYPN forms part of a protein complex involving nebulin and titin which are essential in muscle elasticity and stability. MYPN's presence impacts cellular mechanisms vital in muscle growth and regeneration. It regulates intracellular signaling pathways ensuring muscles respond properly to mechanical stress and maintain their integrity under load.

Pathways

MYPN participates in the MAPK signaling pathway and links with the cytoskeletal regulatory network. In these pathways MYPN works with proteins such as alpha-actinin and titin to mediate cellular responses to mechanical stimuli. These connections highlight its role in maintaining muscle homeostasis. The involvement of MYPN in such pathways signifies its importance in the cellular adaptation process affecting various signal transduction processes and structural developments during muscle contraction and repair.

MYPN mutations associate with conditions like dilated cardiomyopathy and hypertrophic cardiomyopathy. These cardiac diseases show how important MYPN is in maintaining heart muscle function. Mutations can lead to disrupted sarcomere structure causing impaired cardiac function. Additionally the protein connects to titin another sarcomeric protein involved in similar cardiomyopathies highlighting the interplay between sarcomeric proteins in disease mechanisms.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com